Results 11 to 20 of about 88,356 (287)
An Immunosuppressive Antibody–Drug Conjugate [PDF]
Journal of the American Chemical Society, 2015 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E +13 more
openaire +6 more sources
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]
Frontiers in Immunology, 2023 Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld +5 more
doaj +2 more sources
A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development [PDF]
Antibodies, 2019 Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey +4 more
doaj +2 more sources
Communications Medicine, 2021 Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted ...
Seok Jae Lee +10 more
doaj +1 more source
Nature Communications, 2023 Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu +12 more
doaj +1 more source
Practical oncology, 2023 This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova +2 more
+4 more sources
Resistance to Antibody–Drug Conjugates [PDF]
Cancer Research, 2018 Abstract Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent.
García-Alonso, Sara +2 more
openaire +3 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Umbreen Hafeez +3 more
openaire +4 more sources
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
openaire +3 more sources
, 2021 Supplementary Figure from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible ...
Abhay K. Singh (15033101) +5 more
core +4 more sources